newsfilter
← Latest News
GlobeNewswire·

Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights

– Completed Phase 1b studies for ABI-5366 and ABI-1179, helicase-primase inhibitors for recurrent genital herpes – – Completed chronic toxicology studies for ABI-6250, an oral small-molecule entry inhibitor candidate